Logo

Ambry Genetics +RNAinsight

Oct 01, 2019

Ambry Genetics has launched +RNAinsight, a combined DNA and RNA genetic test for hereditary cancer syndromes that is designed to return more certain results to patients by using RNA sequencing to definitively classify otherwise ambiguous genetic alterations. While the RNA aspect of the test does not include all known cancer risk genes, it does focus on a subset that includes BRCA1 and 2, TP53, PTEN, and PALB2, among others. Ambry said that the turnaround time for the combined test matches the company's DNA-only hereditary cancer panel.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.